Cholesterol
Advanced Testing Beyond Basic Panels
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention. These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.
In Brief
Standard lipid panels measure cholesterol content. Cardiovascular risk tracks more closely with particle number and how long that number stays elevated. When cholesterol content and particle number do not match, the standard panel can mislead.
Three tests address what the standard panel does not: ApoB counts the atherogenic particles directly, Lp(a) identifies an inherited risk factor invisible on routine panels, and coronary artery calcium (CAC) scoring shows whether calcified plaque has already formed.
A handful of secondary tests (non-HDL-C, NMR particle analysis, hs-CRP) add value in specific situations. Several other widely marketed tests rarely change decisions.
Not every reader needs every test. This article walks through who is a strong candidate, who is a possible candidate, and who can skip additional testing because their treatment direction is already clear.
Why Advanced Testing Exists
For most people, a standard lipid panel provides useful information. But cholesterol content and particle number do not always agree, and that gap is where the standard panel can mislead.
When cholesterol content and particle number do not match — most often in insulin resistance, elevated triglycerides, metabolic syndrome, and type 2 diabetes — the cholesterol number can look acceptable while particle count is high. Less commonly, fewer larger cholesterol-rich particles can produce LDL-C values that overstate particle burden. Standard panels cannot distinguish these patterns. Advanced testing can.
Should You Consider This Testing?
Before reading about the individual tests, it helps to know whether they are likely to add anything for your situation. Advanced testing is most useful when it would change a decision. When the decision is already clear, more testing rarely changes outcomes.
When Advanced Testing Is Unlikely to Help
If any of the following apply, your treatment direction is already determined by current guidelines:
You already have established cardiovascular disease (prior heart attack, stroke, coronary stent or bypass, diagnosed peripheral artery disease). Treatment is already indicated; the question is intensity, not whether to treat.
Your LDL-C is persistently 190 mg/dL or higher. Guidelines recommend statin therapy regardless of other testing. A familial hypercholesterolemia evaluation may be appropriate.
You have diabetes with additional risk factors (age 40 or older, kidney disease, retinopathy, neuropathy, or other vascular complications). Guidelines already recommend aggressive lipid management.
You are clearly at very low cardiovascular risk (young, no family history, healthy lipid panel, no metabolic risk factors). Standard monitoring is sufficient for now.
When You Are a Strong Candidate
Advanced testing is most useful in the “gray zone,” when your standard risk assessment leaves the treatment decision unclear:
| Situation | What It Suggests | First-Line Test |
| Borderline or intermediate 10-year CV risk (roughly 5–20%) where statin decision is uncertain | Decision could go either way; objective data could resolve it | CAC scoring |
| Strong family history of premature heart disease (men <55, women <65) without explanation from lipid panel | Inherited risk factors may be present that standard panels cannot see | Lp(a) once; consider ApoB |
| LDL-C looks acceptable but you have metabolic syndrome, type 2 diabetes, prediabetes, or insulin resistance | Discordance likely; LDL-C may understate particle burden | ApoB first-line |
| Triglycerides >150 mg/dL with “normal” LDL-C | Small, cholesterol-depleted particles; elevated particle count | ApoB; non-HDL-C as no-cost first look |
| Personal history of premature CV disease, particularly if LDL-C was not dramatically elevated | Inherited risk factor like Lp(a) may have contributed | Lp(a) once; ApoB if not measured |
| First-degree relative with known elevated Lp(a) | Lp(a) is inherited; ~50% of first-degree relatives also elevated | Lp(a) once (cascade testing) |
| South Asian ancestry with any CV risk factor | Higher rates of premature CAD; modest traditional risk factor abnormalities | Lp(a) once; consider ApoB |
A Reasonable Order of Operations
If you fit one of the strong-candidate situations above, a sensible sequence is typically:
1. Start with what you already have. Look at non-HDL-C on your existing lipid panel. This costs nothing and often answers the discordance question when triglycerides are elevated.
2. Measure Lp(a) once. This is a one-time test that provides lifetime information. The 2022 European Atherosclerosis Society consensus and 2021 Canadian Cardiovascular Society guidelines both recommend measuring it at least once in adulthood. (12,15)
3. Add ApoB when discordance is likely. Particularly with elevated triglycerides, metabolic syndrome, diabetes, or a clinical picture that doesn’t match the lipid panel.
4. Consider CAC when the decision is still unclear. If lipid testing doesn’t resolve uncertainty about whether to start treatment, a CAC scan often does.
How to Bring This Up With Your Clinician
A short, specific request usually works better than a vague one. Something like: “Given my [family history / metabolic risk factors / borderline risk / South Asian ancestry / etc.], I would like to discuss whether ApoB, Lp(a), or a CAC scan would help clarify my cardiovascular risk and inform our treatment decision.”
If your clinician orders the test, ask one follow-up question: “What result would change what we do?” That is the single most useful question for separating testing that informs decisions from testing that does not.
ApoB: Counting What Actually Causes Plaque
The question ApoB answers: how many atherogenic particles are circulating?
Atherosclerosis is driven by particles that enter the artery wall, not by cholesterol floating in the bloodstream. So the most direct way to measure cardiovascular risk is to count those particles. That is what ApoB does.
Every atherogenic particle carries one ApoB molecule. (5) This includes LDL (which carries most of the ApoB in circulation), VLDL and its remnants, and Lp(a). Measuring ApoB counts all of these together in a single number. LDL-C, by contrast, measures only the cholesterol inside LDL particles, which can underestimate atherogenic burden when particles are small or when remnant particles are abundant.
Why ApoB Matters When LDL-C Can Mislead
The LDL-C number on most lipid panels is not measured directly; it is calculated from total cholesterol, HDL-C, and triglycerides using the Friedewald equation. (1) That calculation becomes unreliable as triglycerides rise and breaks down entirely when triglycerides exceed approximately 400 mg/dL. Modern equations (Martin/Hopkins, Sampson) are more accurate at elevated triglyceride levels, but they still measure cholesterol content, not particle number. (2,3)
The deeper limitation is biological, not mathematical. In insulin resistance, the liver produces more VLDL, which converts to LDL particles that tend to be smaller and carry less cholesterol each. LDL-C can look acceptable while the actual number of particles, and therefore ApoB, is elevated. (4)
The practical takeaway: in insulin resistance and related conditions, LDL-C can underestimate how many plaque-forming particles are circulating. ApoB exists to count what LDL-C cannot.
Evidence for ApoB
A meta-analysis of 12 prospective studies including 233,455 participants compared LDL-C, non-HDL-C, and ApoB as predictors of cardiovascular events. The relative risk ratios were 1.43 for ApoB, 1.34 for non-HDL-C, and 1.25 for LDL-C. (6) The absolute difference is modest, and the question of whether ApoB should replace LDL-C as the primary lipid target remains debated.
What is less controversial is the narrower claim: when LDL-C and ApoB disagree, ApoB tends to be the closer signal of risk over time.
Interpreting ApoB Results
| ApoB Level | General Interpretation |
| Below 80 mg/dL | Low |
| 80–99 mg/dL | Borderline |
| 100–129 mg/dL | Elevated |
| 130 mg/dL or higher | High; listed as a risk-enhancing factor in the 2018 ACC/AHA guideline (11) |
European guidelines propose ApoB targets stratified by risk category: below 100 mg/dL for lower risk, below 80 mg/dL for high risk, and below 65 mg/dL for very high risk. (16)
Lp(a): The Inherited Risk Factor
The question Lp(a) answers: is there inherited risk that multiplies everything else?
Some people develop cardiovascular disease despite otherwise unremarkable cholesterol panels. Elevated Lp(a) is one of the most common reasons.
Lp(a), pronounced “L-P-little-a,” is an LDL-like particle with an extra protein called apolipoprotein(a) attached. Like LDL, it carries ApoB and can enter the artery wall. But Lp(a) does damage through several overlapping pathways at once: it promotes atherosclerosis, drives arterial inflammation, interferes with the body’s ability to break down clots, and contributes to calcific aortic valve disease. (7,12)
Why Lp(a) Deserves Attention
When Lp(a) is elevated, clinicians often pursue more intensive management of every modifiable risk factor: lower LDL-C and ApoB targets, tighter blood pressure control, smoking cessation, and glycemic optimization. The reason is that Lp(a) itself cannot currently be changed by lifestyle or therapy, so the strategy shifts to compressing every other contributor to arterial injury.
Knowing about elevated Lp(a) therefore changes treatment intensity in a way that nothing else on a standard panel can. Yet most people have never had it measured.
Elevated Lp(a) is one of the most common inherited cardiovascular risk factors, affecting an estimated 10–20% of adults globally. (12) It is also disproportionately common in people who develop premature coronary disease, with prevalence figures around 25–30% reported in cohorts of patients with early myocardial infarction. (7,12) For these reasons, the 2022 European Atherosclerosis Society consensus and 2021 Canadian Cardiovascular Society guidelines recommend measuring Lp(a) at least once in all adults. (12,15)
The Genetic Reality
Lp(a) levels are approximately 90% genetically determined. (7) Diet, exercise, and weight loss do not meaningfully lower Lp(a). Standard statins do not lower it and may modestly increase it on average. (12) Because levels are stable throughout life, a single measurement provides lifetime information.
This is why Lp(a), when elevated, is the cardiovascular risk factor with the longest exposure window. The arteries have already been exposed to elevated Lp(a) for decades before the test is ever measured.
Ethnic Differences in Lp(a)
Lp(a) levels vary substantially across populations. Data from 460,506 UK Biobank participants: (13)
| Population | Median Lp(a) |
| White European | 19 nmol/L |
| South Asian | 31 nmol/L |
| Black | 75 nmol/L |
| Chinese | 16 nmol/L |
Importantly, the relationship between Lp(a) and cardiovascular risk is broadly similar across ethnic groups. In the same UK Biobank analysis, hazard ratios for cardiovascular events per 50 nmol/L increment in Lp(a) were 1.11 in White, 1.10 in South Asian, and 1.07 in Black individuals. (13) Higher Lp(a) means higher risk regardless of ancestry; what differs is how common elevated Lp(a) is in each population.
Interpreting Lp(a) Results
Lp(a) can be reported in mg/dL or nmol/L. These units are not directly convertible because the conversion factor varies with apolipoprotein(a) isoform size. Always note which unit your lab uses.
| Lp(a) Level | Interpretation |
| Below 75 nmol/L (below ~30 mg/dL) | Lower risk |
| 75–125 nmol/L (~30–50 mg/dL) | Intermediate — “gray zone” |
| 125–250 nmol/L (~50–100 mg/dL) | Elevated; risk enhancer |
| Above 250 nmol/L (above ~100 mg/dL) | High; substantially increased risk |
The 2022 EAS consensus suggests using 125 nmol/L or higher to “rule in” risk and below 75 nmol/L to “rule out” risk, with 75–125 nmol/L as a gray zone requiring clinical judgment. (12)
Clinical Approach When Lp(a) Is Elevated
No approved therapies currently lower Lp(a) sufficiently to reduce cardiovascular events. PCSK9 inhibitors lower Lp(a) modestly (roughly 20–30%), but their cardiovascular benefit comes primarily from LDL-C reduction. (7) Because Lp(a) itself cannot be modified with current therapy, optimization of modifiable risk factors becomes even more important:
• More intensive LDL-C and ApoB lowering, often to targets below those used in patients with normal Lp(a)
• Tighter blood pressure control
• Glycemic optimization
• Smoking cessation
• Aspirin may be discussed in selected patients, but this requires individualized assessment
Several Lp(a)-specific therapies (pelacarsen, olpasiran, lepodisiran) are in late-stage development. Phase 2 data show substantial Lp(a) reductions. The critical unanswered question is whether lowering Lp(a) reduces cardiovascular events; outcome trials are ongoing.
Because Lp(a) is inherited, roughly half of first-degree relatives of someone with markedly elevated Lp(a) will also have elevated levels. Cascade testing of parents, siblings, and children is recommended by EAS guidelines. (12)
Coronary Artery Calcium Scoring: Seeing What Blood Tests Cannot
The question CAC answers: has calcified plaque already formed?
Blood tests measure risk factors. CAC shows whether those risk factors have already produced detectable disease.
Consider two 58-year-old patients with identical lipid profiles, no diabetes, and no smoking history. The standard risk calculator gives them the same 10-year risk estimate. One has a CAC score of 0; the other has a CAC of 285. They do not have the same cardiovascular risk, and they should not be managed the same way.
What CAC Measures
CAC scoring uses a low-dose CT scan, without contrast, to detect and quantify calcium deposits in the coronary arteries. Calcified deposits are a marker of established atherosclerotic plaque. The scan takes about ten minutes and produces a numerical Agatston score. (10,11)
CAC detects calcified plaque specifically. It does not detect non-calcified plaque, which can be present in earlier disease, particularly in younger individuals.
Interpreting CAC Results
| CAC Score | Clinical Implication |
| 0 | No calcified plaque detectable. In intermediate-risk patients, can support deferring statin therapy, with exceptions. (11) |
| 1–99 | Mild calcified atherosclerosis. Generally favors statin therapy, particularly age 55+. (11) |
| 100–399 | Moderate calcified atherosclerosis. CAC ≥100 or >75th percentile for age/sex generally favors statin therapy. (11) |
| 400 or higher | Extensive calcified atherosclerosis. Substantially higher event rates; guidelines favor intensive prevention. (10,11) |
A CAC of zero is one of the more reassuring findings in cardiovascular risk assessment. In the MESA cohort, individuals with CAC = 0 had 10-year cardiovascular event rates in the low single digits across age, sex, and race/ethnicity subgroups. (17) But CAC = 0 does not mean zero risk. Guidelines specify that CAC of zero should not defer treatment in: diabetes with other risk factors, LDL-C persistently above 190 mg/dL, strong family history of premature cardiovascular disease, current smoking, or elevated Lp(a). (11)
A CAC of zero also has a meaningful but finite “warranty period.” MESA follow-up data suggest that progression to CAC > 0 typically takes 3–5 years in higher-risk patients and longer in lower-risk patients. (18)
Any CAC above zero indicates that calcified atherosclerosis is present. The disease process has begun regardless of what the lipid panel shows.
When CAC Is Used as a Decision Aid
The 2018 ACC/AHA cholesterol guideline frames CAC as a decision aid when the statin decision remains uncertain after standard risk assessment. (11) Common scenarios: intermediate 10-year ASCVD risk (5–20%) with uncertainty about treatment intensity; borderline risk (5–7.5%) with risk-enhancing factors present; patient preference for additional information before starting medication.
When CAC Is Generally Not Appropriate
CAC is not appropriate when: cardiovascular disease is already established; treatment is clearly indicated regardless (LDL-C ≥190 mg/dL, high-risk diabetes); very young age (under 40) without strong family history; or pregnancy.
Practical Considerations
Radiation exposure is low. Incidental findings (lung nodules, thyroid abnormalities) occasionally require follow-up. Cost varies widely, typically $75–$400 in the US. Coverage by insurance is improving but inconsistent.
Secondary Tests: When You Need More Than the Big Three
ApoB, Lp(a), and CAC answer most clinical questions. The tests below are second-line tools, useful in specific situations.
Non-HDL-C: The No-Cost Starting Point
You already have this number. Non-HDL-C is total cholesterol minus HDL-C, and it appears on every standard lipid panel. It captures cholesterol carried in all atherogenic particles (LDL, VLDL, remnants, and Lp(a)), not just LDL. When triglycerides are elevated, non-HDL-C provides a better estimate of atherogenic exposure at no additional cost.
Non-HDL-C thresholds are typically 30 mg/dL higher than the corresponding LDL-C thresholds: (11)
| LDL-C Goal | Non-HDL-C Goal |
| Below 100 mg/dL | Below 130 mg/dL |
| Below 70 mg/dL | Below 100 mg/dL |
| Below 55 mg/dL | Below 85 mg/dL |
Best use: first-line check when triglycerides are elevated; tracking metric when ApoB testing is not available.
NMR LipoProfile: When You Need Particle Detail
Nuclear magnetic resonance spectroscopy measures LDL particle number (LDL-P) and particle size directly. (8) Reference ranges are lab-specific:
| Measurement | Optimal | Borderline | Elevated |
| LDL-P (nmol/L) | Below ~1,000 | ~1,000–1,299 | ~1,300 or higher |
Best use: when ApoB and LDL-C are discordant and the underlying particle pattern would change management. Limitation: ApoB provides the clinically actionable number more simply. NMR adds detail that rarely changes what happens next.
hs-CRP: An Inflammation Signal
High-sensitivity C-reactive protein measures systemic inflammation. It is not a lipid test, but it is often ordered alongside lipids. (9)
| hs-CRP | Interpretation |
| Below 1.0 mg/L | Lower inflammatory risk |
| 1.0–3.0 mg/L | Average inflammatory risk |
| Above 3.0 mg/L | Higher inflammatory risk |
| Above 10 mg/L | Likely an acute process; retest when healthy |
The 2018 ACC/AHA guideline identifies hs-CRP ≥2.0 mg/L as a risk-enhancing factor. (11)
Best use: borderline-risk patients where an additional risk enhancer might shift the treatment decision. Limitation: hs-CRP is nonspecific. Infection, recent injury, autoimmune disease, obesity, and intense exercise all raise it.
Tests That Often Do Not Change Routine Clinical Decisions
| Test | Why It’s Limited |
| Oxidized LDL | Not standardized; research tool |
| Small dense LDL (gel electrophoresis) | Information captured by ApoB |
| Lp-PLA2 | Inconsistent predictive value |
| Homocysteine | Lowering it has not reduced cardiovascular events |
Putting It Together: Resolving Conflict Between Tests
When Results Conflict
The general hierarchy when tests disagree:
1. CAC: shows calcified coronary atherosclerosis already present
2. ApoB: counts the particles that drive disease
3. Lp(a): identifies inherited risk multiplier
4. Non-HDL-C: better than LDL-C when triglycerides are elevated
5. Calculated LDL-C: least reliable when discordance is present
A clinician confronted with conflicting results generally puts the most weight on findings that reflect actual disease (CAC) over those that reflect risk factors, and on findings that count particles (ApoB, Lp(a)) over those that measure cholesterol content (LDL-C).
Two Patterns That Illustrate the Framework
These are illustrative, not specific diagnostic thresholds. The point is the pattern, not the exact numbers.
Pattern A — Hidden risk: discordant labs with plaque
• LDL-C: 95 mg/dL (looks acceptable)
• Triglycerides: 220 mg/dL (elevated)
• HDL-C: 36 mg/dL (low)
• ApoB: 110 mg/dL (elevated)
• Lp(a): 25 nmol/L (normal)
• CAC: 150 (moderate plaque)
This is the metabolic syndrome pattern: elevated triglycerides and low HDL-C signal insulin resistance, LDL particles are smaller and cholesterol-depleted. LDL-C looks fine; ApoB reveals elevated particle count; CAC confirms atherosclerosis is present. Per guidelines, CAC ≥100 favors statin therapy.
Pattern B — Inherited risk: borderline numbers with elevated Lp(a)
• LDL-C: 110 mg/dL (borderline)
• Triglycerides: 95 mg/dL (normal)
• HDL-C: 58 mg/dL (normal)
• ApoB: 95 mg/dL (borderline)
• Lp(a): 180 nmol/L (high)
• CAC: 50 (mild plaque)
The metabolic picture is unremarkable: ApoB and LDL-C are concordant and only borderline elevated. But Lp(a) is significantly elevated, and early calcified plaque is already present. This pattern often shifts decisions toward more intensive management. Cascade testing of first-degree relatives is often considered.
Practical Matters: Getting Accurate Results
Fasting and Timing by Test
| Test | Fasting? | Best Timing | What Can Affect Results |
| Standard lipid panel | Usually not required | Stable health | Recent illness, alcohol, rapid weight change |
| ApoB | Usually not required | Stable health | Same as lipid panel |
| Lp(a) | No | Anytime | Almost nothing — genetically fixed |
| NMR LipoProfile | Many labs request it | Stable health | Recent food intake |
| hs-CRP | No | When healthy | Any inflammation |
| CAC scan | No | Anytime | Nothing significant |
Non-fasting samples are acceptable for routine screening. (11) Fasting mainly matters when triglycerides are elevated, when evaluating discordance, or when tracking changes over time.
How Often These Tests Are Repeated
| Test | Typical Approach |
| Standard lipid panel | Every 4–6 years if normal/low risk; annually if elevated or on therapy |
| ApoB | More often if abnormal or on therapy; every few years if stable |
| Lp(a) | Once in a lifetime |
| hs-CRP | Confirm elevated results when healthy; not needed routinely once baseline established |
| CAC | If zero: retesting after several years. If positive: only if result would change management |
Insurance and Costs
Approximate US self-pay ranges:
| Test | Typical Cash Price |
| ApoB | $25–$50 |
| Lp(a) | $50–$100 |
| NMR LipoProfile | $99–$150 |
| hs-CRP | $20–$40 |
| CAC scan | $75–$400 |
To improve coverage likelihood, have your clinician document specific risk enhancers and state that the result will guide treatment intensity.
Common Questions
“My LDL looks fine but heart disease runs in my family. What tests should I discuss?”
Lp(a) (once in a lifetime) and ApoB are commonly considered, as they can reveal inherited risk and particle discordance that standard panels miss. If results are ambiguous and 10-year risk is borderline, CAC scanning often resolves uncertainty.
“If ApoB is high but LDL-C is normal, what does that mean?”
Cardiovascular risk tracks with ApoB when the two disagree. ApoB ≥130 mg/dL is a risk-enhancing factor in guidelines. This discordance pattern, common in metabolic syndrome and insulin resistance, often shifts decisions toward treatment.
“Can lifestyle meaningfully lower ApoB?”
Lifestyle can lower ApoB, especially when insulin resistance, excess weight, elevated triglycerides, or high alcohol intake are contributing. Lower refined-carbohydrate intake and reduced alcohol typically lower triglycerides and remnant particles. But genetics constrain how far lifestyle can take any individual.
“My CAC is zero. Does that mean I’m fine?”
A CAC of zero is reassuring for near-term risk, but it is not a permanent pass. CAC detects calcified plaque, not non-calcified plaque. Risk accumulates over time. A CAC of zero in someone with very high LDL-C, elevated Lp(a), diabetes, or active smoking does not necessarily mean treatment should be deferred.
“My Lp(a) is high. Can I lower it?”
Not meaningfully with currently approved therapies. The clinical strategy is to treat elevated Lp(a) as a fixed multiplier and reduce every other modifiable risk factor more aggressively. Several Lp(a)-specific therapies are in late-stage trials.
“Should everyone get these tests?”
Advanced testing adds the most value in the gray zone, where standard assessment leaves the decision unclear. In patients with known cardiovascular disease, very high LDL-C, or high-risk diabetes, guidelines already recommend treatment. In clearly low-risk patients, standard monitoring is sufficient.
The Bottom Line
Two people with the same LDL-C can carry meaningfully different cardiovascular risk. One may have elevated particle exposure hidden behind a reassuring number. Another may have LDL-C that overstates their actual atherogenic exposure. Standard panels cannot distinguish these patterns. Advanced testing can.
ApoB counts the particles that actually drive atherosclerosis. Lp(a) identifies inherited risk invisible on routine panels. CAC scoring shows whether calcified disease has already developed. These three tests answer the questions standard lipid panels cannot.
The central principle is straightforward: standard panels measure cholesterol content, but arteries respond to particle number and cumulative exposure over time. When those two signals diverge, the standard panel quietly understates risk.
Understanding this framework does not change genetics or erase prior exposure. It changes how risk is recognized, interpreted, and managed going forward.
Next: Article 3 covers lifestyle approaches to lipid management: what works, what doesn’t, and how much realistic impact to expect.
Key Terms
ApoB (apolipoprotein B): A protein found on LDL, VLDL, IDL, and Lp(a) particles, one per particle. Measuring ApoB counts total atherogenic particles directly.
Lp(a): An LDL-like particle with apolipoprotein(a) attached. Levels are approximately 90% genetic, stable for life, and not modified by lifestyle. Promotes atherosclerosis, inflammation, and thrombosis.
CAC (coronary artery calcium) score: CT-based measurement of calcium deposits in coronary arteries. Indicates presence and extent of calcified atherosclerotic plaque.
Discordance: When LDL-C and particle number disagree. Common in insulin resistance, metabolic syndrome, and elevated triglycerides.
Non-HDL-C: Total cholesterol minus HDL-C. Captures cholesterol in all atherogenic particles; useful when advanced testing is unavailable.
Risk enhancer: A clinical feature that increases cardiovascular risk beyond what standard calculators capture, potentially favoring treatment in borderline or intermediate-risk individuals.
Friedewald equation: Standard calculation for LDL-C using total cholesterol, HDL-C, and triglycerides. Accuracy decreases as triglycerides rise.
References
1. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
2. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels. JAMA. 2013;310(19):2061–2068.
3. Sampson M, Ling C, Sun Q, et al. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540–548.
4. Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105–113.
5. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4(12):1287–1295.
6. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–345.
7. Tsimikas S. A test in context: lipoprotein(a) — diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
8. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26(4):847–870.
9. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
10. Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434–447.
11. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143.
12. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–3946.
13. Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41(1):465–474.
14. Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA. 2007;297(3):286–294.
15. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–1150.
16. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
17. Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J. 2018;39(25):2401–2408.
18. Dzaye O, Dardari ZA, Cainzos-Achirica M, et al. Warranty period of a calcium score of zero: comprehensive analysis from MESA. JACC Cardiovasc Imaging. 2021;14(5):990–1002.
19. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016.
20. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation. 2003;107(3):499–511.
HeartBuddi • Your heart. Own it.